LLY - What's Happening With Eli Lilly Shares On Monday? | Benzinga
Eli Lilly and Co (NYSE:LLY) shared detailed results from the SYNERGY-NASH phase 2 study on Saturday.
This trial involved 190 patients, both with and without type 2 diabetes, evaluating tirzepatide in adults with biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) and stage 2 or 3 fibrosis.
The study’s primary endpoint was met, with 51.8%, 62.8%, and 73.3% of participants taking 5 mg, 10 mg, and 15 mg doses, respectively, achieving MASH resolution without fibrosis worsening compared to 13.2% on placebo at 52 weeks.
Presented at the European Association for the Study of the Liver (EASL) Congress 2024 and published in The New England Journal of Medicine, the data also showed secondary endpoint results.
In a secondary endpoint, participants taking 5 mg, ...